Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States

Malin Hultcrantz; David Kleinman; Ravi Vij; Fernando Escalante; Michel Delforge; Nirali Kotowsky; Jacopo Bitetti; Natalie Boytsov; Leena Camadoo-O’Byrne; Lindsey Powers Happ; Guillaume Germain; Ana Urosevic; Malena Mahendran; Mei Sheng Duh; François Laliberté; Michele Cavo; Hans C. Lee

doi:10.3324/haematol.2024.285893

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States

Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Michel Delforge, Nirali Kotowsky, Jacopo Bitetti, Natalie Boytsov, Leena Camadoo-O’Byrne, Lindsey Powers Happ, Guillaume Germain, Ana Urosevic, Malena Mahendran, Mei Sheng Duh, François Laliberté, Michele Cavo, Hans C. Lee

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	753-757
Number of pages	5
Journal	Haematologica
Volume	110
Issue number	3
DOIs	https://doi.org/10.3324/haematol.2024.285893
State	Published - Mar 2025

Access to Document

10.3324/haematol.2024.285893

Cite this

Hultcrantz, M., Kleinman, D., Vij, R., Escalante, F., Delforge, M., Kotowsky, N., Bitetti, J., Boytsov, N., Camadoo-O’Byrne, L., Happ, L. P., Germain, G., Urosevic, A., Mahendran, M., Duh, M. S., Laliberté, F., Cavo, M., & Lee, H. C. (2025). Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States. Haematologica, 110(3), 753-757. https://doi.org/10.3324/haematol.2024.285893

@article{e5ea1b59dec444f9af34a852df9b4b09,

title = "Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States",

author = "Malin Hultcrantz and David Kleinman and Ravi Vij and Fernando Escalante and Michel Delforge and Nirali Kotowsky and Jacopo Bitetti and Natalie Boytsov and Leena Camadoo-O{\textquoteright}Byrne and Happ, {Lindsey Powers} and Guillaume Germain and Ana Urosevic and Malena Mahendran and Duh, {Mei Sheng} and Fran{\c c}ois Lalibert{\'e} and Michele Cavo and Lee, {Hans C.}",

year = "2025",

month = mar,

doi = "10.3324/haematol.2024.285893",

language = "English",

volume = "110",

pages = "753--757",

journal = "Haematologica",

issn = "0390-6078",

number = "3",

}

Hultcrantz, M, Kleinman, D, Vij, R, Escalante, F, Delforge, M, Kotowsky, N, Bitetti, J, Boytsov, N, Camadoo-O’Byrne, L, Happ, LP, Germain, G, Urosevic, A, Mahendran, M, Duh, MS, Laliberté, F, Cavo, M & Lee, HC 2025, 'Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States', Haematologica, vol. 110, no. 3, pp. 753-757. https://doi.org/10.3324/haematol.2024.285893

TY - JOUR

T1 - Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma

T2 - a real-world observational study in the United States

AU - Hultcrantz, Malin

AU - Kleinman, David

AU - Vij, Ravi

AU - Escalante, Fernando

AU - Delforge, Michel

AU - Kotowsky, Nirali

AU - Bitetti, Jacopo

AU - Boytsov, Natalie

AU - Camadoo-O’Byrne, Leena

AU - Happ, Lindsey Powers

AU - Germain, Guillaume

AU - Urosevic, Ana

AU - Mahendran, Malena

AU - Duh, Mei Sheng

AU - Laliberté, François

AU - Cavo, Michele

AU - Lee, Hans C.

PY - 2025/3

Y1 - 2025/3

UR - http://www.scopus.com/inward/record.url?scp=86000311820&partnerID=8YFLogxK

U2 - 10.3324/haematol.2024.285893

DO - 10.3324/haematol.2024.285893

M3 - Letter

C2 - 39415693

AN - SCOPUS:86000311820

SN - 0390-6078

VL - 110

SP - 753

EP - 757

JO - Haematologica

JF - Haematologica

IS - 3

ER -

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States

Access to Document

Other files and links

Cite this